In‐hospital mortality (adult and paediatric patients) · patients with severe sepsis or septic shock
Human recombinant activated protein C showed no clear difference in in‐hospital mortality (adult and paediatric patients) compared with placebo (moderate certainty).
1 finding from 1 review
28‐Day all‐cause mortality (adult and paediatric patients) · patients with severe sepsis or septic shock
Human recombinant activated protein C showed no clear difference in 28‐Day all‐cause mortality (adult and paediatric patients) compared with placebo (moderate certainty).
1 finding from 1 review
Mortality in paediatric population (subgroup) · critically ill participants with ALI and ARDS
INO showed no clear difference in mortality in paediatric population (subgroup) compared with control group (moderate certainty).
1 finding from 1 review
RR 0.78 [0.51, 1.18]
185 participants
Moderate
All‐cause mortality · Adult patients with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in mortality compared with inpatients ‐ adults (moderate certainty).
1 finding from 1 review
All‐cause mortality · Children with cancer who develop a low‐risk febrile neutropaenic event
Outpatients showed no clear difference in mortality compared with inpatients ‐ children (moderate certainty).
1 finding from 1 review
All‐cause mortality · paediatric patients following heart surgery
Prophylactic levosimendan showed no clear difference in mortality compared with standard treatment (low certainty).
1 finding from 1 review
All‐cause mortality · paediatric participants with appendiceal abscess
1 finding from 1 review
Mortality Median · paediatric and adult patients with appendiceal phlegmon
1 finding from 1 review
Patient mortality · patients admitted to a cardiovascular surgery/urology/ophthalmology unit, a kidney transplant/plastic surgery unit, an oncology unit, or…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at 12 months · adults with dementia following hip fracture surgery
It is very uncertain whether geriatrician‐led inpatient management changes mortality at 12 months compared with orthopaedic‐led inpatient management (very low certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory paediatric cancer patients newly diagnosed with acute lymphoblastic leukaemia who received chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality (up to 90 days) · orthopaedic (hip)
1 finding from 1 review
Mortality (up to 90 days) · orthopaedic (mixed)
It is very uncertain whether cell salvage changes mortality (up to 90 days) compared with no cell salvage (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality within 30 days of · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
1 finding from 1 review
Intervention not reported
Mortality within 30 days of · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
1 finding from 1 review
Intervention not reported
Mortality within the longest · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
The intervention showed no clear difference in mortality within the longest (low certainty).
1 finding from 1 review
Intervention not reported
Mortality within the longest · surgical patients with need for abdominal, caesarean section, orthopaedic or breast surgery
It is very uncertain whether the intervention changes mortality within the longest (very low certainty).
1 finding from 1 review
Mortality within the longest · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (at longest compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
All‐cause mortality (up to 30 days) · adults undergoing non‐cardiac surgery
Continuation showed no clear difference in all‐cause mortality (up to 30 days) compared with discontinuation of antiplatelet therapy (low certainty).
1 finding from 1 review
Mortality (up to 90 days) ‐ not reported · orthopaedic (knee)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found